Please login to the form below

Not currently logged in
Email:
Password:

Damien McDevitt moves from GSK to Acadia Pharmaceuticals

Takes up position as SVP, corporate development at the US biopharma firm

Acadia Damien McDevittUS biopharmaceutical company Acadia Pharmaceuticals has appointed Damien McDevitt (pictured) as senior vice president of corporate development.

He joins the San Diego-based firm from GlaxoSmithKline, where he spent more than two decades, most recently serving as VP, head of business development for R&D extended therapy areas and head of its R&D West Coast Satellite.

Prior to that, McDevitt held positions with increasing responsibility within worldwide business development at GSK Ventures and Anti-Infectives Discovery.

At Acadia, which focuses on the development and commercialisation of medicines for central nervous system (CNS) disorders, McDevitt will report to the company’s president and chief executive officer Steve Davis.

He said: “We are thrilled to welcome Damien to the team. Damien has extensive experience in business development, licensing and strategic partnering, and he has completed dozens of value-creating transactions. This expertise, combined with his strong strategic and technical background, will be of great value as we continue to explore the potential for expanding our CNS portfolio.”

Meanwhile, Acadia’s SVP, technology development and operations Jim Nash will retire in January. The company’s former SVP, strategy and business development Bob Mischler will assume responsibilities for technology development and operations in addition to continuing his strategy responsibilities in the new role of SVP, strategy and technology operations.

21st December 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics